Orexo’s Rapinyl to be marketed in CIS, Romania and Bulgaria
Orexo AB and the Hungarian pharmaceutical company Gedeon Richter have announced that they have entered into a distribution agreement under which Gedeon Richter accrues the exclusive rights to market and sell Rapinyl, Orexo’s patented product for management of breakthrough cancer pain. The agreement will cover CIS countries, Bulgaria, and Romania.
According to Zsolt Lavotha, president and CEO of Orexo, the company sees significant opportunities for pharmaceuticals in general and for innovative products such as Rapinyl in particular due to increasing purchasing power in Russia.
